pAMP Platform
Proprietary multi-epitope concatemeric peptide technology delivering broad immune coverage against complex pathogens.
Delaware, USA · Biodefense Biotechnology
Next-Generation Biodefense Vaccines
Kinexar Bio develops precision concatemeric peptide platforms for biological threats with no approved medical countermeasures.
The Gap
High-consequence pathogens still have no countermeasures.
Emerging and weaponizable pathogens outpace conventional vaccine development. Kinexar Bio's platform is purpose-built for the threats where speed, stability, and breadth of immune coverage matter most — and where no approved vaccine exists today.
35–40%
Case fatality rate of Hantavirus Pulmonary Syndrome
Zero
Approved vaccines or therapeutics for HPS
Category A
CDC biodefense priority designation
No cold chain
Thermostable formulation for field deployment
Platform
Built on pAMP and DNA-FACE
A concatemeric peptide architecture that assembles many immune targets into a single, manufacturable construct.
DNA-FACE Technology
Enables precise assembly of repeating bioactive peptide units, producing thermostable, non-replicating vaccine constructs.
Thermostable
Cold-chain independent formulation suitable for field deployment in resource-limited settings.
Scalable Manufacturing
Compatible with standard recombinant protein production — no live virus, no complex biologics infrastructure required.
Proven Versatility
Platform has demonstrated biological activity across multiple indications including infectious disease and wound healing applications.
Non-Replicating
No live or attenuated virus in the construct, supporting a favorable safety profile and streamlined biosafety handling.
Pipeline Snapshot
Lead program: KNX-001 for Hantavirus Pulmonary Syndrome
A pAMP-based vaccine candidate against Andes virus (ANDV), designed to elicit broad neutralizing antibody and T-cell responses.
| Program | Pathogen | Indication | Stage | Funding Pathway |
|---|---|---|---|---|
| KNX-001 | Andes Virus (ANDV) | Hantavirus Pulmonary Syndrome (HPS) | Preclinical | BARDA NIH |
Swipe the table horizontally to see all columns.
Leadership
Operators and scientists building for the federal mission
Devrim Aran
President & Chief Executive Officer
Biopharmaceutical executive and entrepreneur with a track record across drug development, regulatory strategy, clinical trials, and international licensing.
Dr. Omar Ahmed
Chief Strategy Officer & Chief Scientific Officer
Scientific and strategic leader overseeing research strategy, know-how transfer, and grant submissions including BARDA and NIH applications.
Partner with Kinexar Bio
We welcome inquiries from government program officers, strategic partners, and investors focused on medical countermeasures.